Aberrant T-cell function  subsequently accompanied by elevated TNF-α levels induces inflammatory symptoms in patients with Behçet’s disease (BD).[2, 3] Subsequently treatment usually involves T-cel directed immunosuppressive or anti-TNF-α therapy in patients with severe disease.    Administration of the new human monoclonal TNF-α antibody adalimumab has only been described in three BD patients with uveitis. We analyzed the effects of adalimumab on severe and often chronic disease in 6 heavily pretreated BD patients with immunosuppressive therapy failure (Table).
- Behcet disease
- TNF alpha inhibitor